Truist upgrades Evolent Health stock rating on valuation, 2027 outlook
Truist upgraded Evolent Health (EVH) to Buy with a $6.00 price target, citing undervaluation and improved 2027 outlook. The stock is down 30% week-to-date, trading at $3.43. Truist expects 2027 adjusted EBITDA midpoint to be at least $150M. EVH reported Q3 earnings meeting profit forecasts, with revenue at $725.4M and adjusted EBITDA at $34.3M, exceeding prior outlook.
How this was made
The 30-second read
Why it matters
The buy rating and $6 target could attract new buying interest, supporting a short‑term rally.
Market read
Analyst upgrade provides a fresh catalyst for EVH, offering a potential entry point for traders.
What to watch
Potential downside from Medicare‑For‑All legislation and Medicaid attrition could pressure earnings.
Background
Truist Securities highlighted valuation gaps and a more favorable 2027 EBITDA outlook as the basis for the upgrade.
Ticker impact
Truist upgraded Evolent Health (EVH) to Buy from Hold with a $6 price target, citing improved 2027 outlook and valuation.
upward pressure as investors price in the buy rating and target.
Analyst upgrade with concrete valuation and guidance range is a fresh catalyst that can move the stock.
Market effects
May lift sentiment in the healthcare services sector as a peer receives a buy rating.
Limited to U.S. markets; no broader regional effect.
Minimal global impact beyond EVH investors.
Counterpoint
The upgrade may be premature if Medicaid policy risks materialize, potentially limiting upside.
Key entities
- analystTruist Securities
Research firm issuing the upgrade.
- companyEvolent Health
Healthcare technology firm receiving the upgrade.



